Antisense Oligonucleotides and RNA Interference - Challenges in Delivery of Therapeutic Genomics and Proteomics - page 378

[146] Henry SP, Giclas PC, Leeds J, Pangburn M, Auletta C, Levin AA, et al. Activation of
the alternative pathway of complement by a phosphorothioate oligonucleotide: potential
mechanism of action. J Pharmacol Exp Ther 1997;281:810-16.
[147] Agrawal S, Zhang X, Cai Q, Kandimalla ER, Manning A, Jiang Z, et al. Effect of aspi-
rin on protein binding and tissue disposition of oligonucleotide phosphorothioate in
rats. J Drug Targeting 1998;5:303-12.
[148] Cossum PA, Truong L, Owens SR, Markham PM, Shea JP, Crooke ST. Pharmacokinetics
of a 14C-labeled phosphorothioate oligonucleotide, ISIS 2105, after intradermal admin-
istration to rats. J Pharmacol Exp Ther 1994;269:89-94.
[149] Nicklin PL, Bayley D, Giddings J, Craig SJ, Cummins LL, Hastewell JG, et al.
Pulmonary bioavailability of a phosphorothioate oligonucleotide (CGP 64128A): com-
parison with other delivery routes. Pharm Res 1998;15:583-91.
[150] Beck GF, Irwin WJ, Nicklin PL, Akhtar S. Interactions of phosphodiester and phos-
phorothioate oligonucleotides with intestinal epithelial Caco-2 cells. Pharm Res
1996;13:1028-37.
[151] Graham MJ, Crooke ST, Monteith DK, Cooper SR, Lemonidis KM, Stecker KK, et al.
In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat
liver after intravenous administration. J Pharmacol Exp Ther 1998;286:447-58.
[152] Zhang H, Cook J, Nickel J, Yu R, Stecker K, Myers K, et al. Reduction of liver Fas
expression by an antisense oligonucleotide protects mice from fulminant hepatitis. Nat
Biotechnol 2000;18:862-7.
[153] Li SD, Huang L. Non-viral is superior to viral gene delivery. J Control Release 2007;
123:181-3.
[154] Verma IM, Somia N. Gene therapy—promises, problems and prospects. Nature 1997;
389:239-42.
[155] Raizada MK, Katovich MJ, Wang H, Berecek KH, Gelband CH. Is antisense gene ther-
apy a step in the right direction in the control of hypertension? Am J Physiol Heart Circ
Physiol 1999;277:H423-32.
[156] Flotte TR, Carter BJ. Adeno-associated virus vectors for gene therapy. Gene Ther
1995;2:357-62.
[157] Akhtar S, Benter IF. Nonviral delivery of synthetic siRNAs in vivo . J Clin Invest
2007;117:3623-32.
[158] McKeon J, Khaledi MG. Evaluation of liposomal delivery of antisense oligonucleotide
by capillary electrophoresis with laser-induced fluorescence detection. J Chromatogr A
2003;1004:39-46.
[159] Meng J, Wang H, Hou Z, Chen T, Fu J, Ma X, et al. Novel anion liposome-encapsulated
antisense oligonucleotide restores susceptibility of methicillin-resistant Staphylococcus
aureus and rescues mice from lethal sepsis by targeting mecA. Antimicrob Agents
Chemother 2009;53:2871-8.
[160] Meidan VM, Glezer J, Salomon S, Sidi Y, Barenholz Y, Cohen JS, et al. Specific
lipoplex-mediated antisense against Bcl-2 in breast cancer cells: a comparison between
different formulations. J Liposome Res 2006;16:27-43.
[161] Resina S, Abes S, Turner JJ, Prevot P, Travo A, Clair P, et al. Lipoplex and peptide-
based strategies for the delivery of steric-block oligonucleotides. Int J Pharm 2007;344:
96-102.
[162] Gao X, Kim KS, Liu D. Nonviral gene delivery: what we know and what is next. AAPS
J 2007;9:E92-E104.
[163] Huang Jr Z, Li Jr W, MacKay Jr JA, Szoka Jr F. Thiocholesterol-based lipids for
ordered assembly of bioresponsive gene carriers. Mol Ther 2005;11:409-17.